Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observation period of approximately 3 years. Median overall...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L., Younes, Anas
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2015
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4335079/
https://ncbi.nlm.nih.gov/pubmed/25533035
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-08-595801
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker